Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04301401
Other study ID # NIMAO/2019-01/LA-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2020
Est. completion date October 10, 2023

Study information

Verified date November 2023
Source Centre Hospitalier Universitaire de Nimes
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Several studies have shown interactions between vaginal microbiota and post-surgical evolution. A study conducted by our team showed a tendency for patients with complications to have a greater diversity of vaginal microbiota. The main objective of the proposed study will therefore be to evaluate the vaginal, urinary and digestive microbiota modifications during and after vaginal surgery and to correlate them with the symptoms of the urogynecological sphere.


Description:

In gynecological surgery, surgical site infections are a common complication. Gynecological surgery and, more specifically, vaginal surgery leads to a high risk of infection not only due to its " clean-contaminated " nature related to the proximity of the vagina but also due to the use of a transvaginal mesh or suburetal sling. The germs most commonly found at the origin of a surgical site infection are germs forming part of the vaginal flora. Furthermore, in the field of pelvic organ prolapse surgery, certain specific complications such as mesh retraction and mesh exposure may be related to infection due to bacterial colonisation. The vaginal ecosystem contains a large quantity of bacteria, the commonest of which are lactobacilli. This ecosystem varies in women depending on their sexuality, hormonal impregnation, tobacco consumption or hygiene.It has been demonstrated that the microbiota can be divided into 7 classes depending on the predominant types of germ. It has also been shown that an imbalance in vaginal flora could be responsible for infections of the upper genital tract, obstetric complications or even the transmission of sexually transmissible diseases. Several studies have shown interactions between the microbiota and post surgical evolution. A recent study carried out at the Gynecology and Obstetrics department of Nîmes University Hospital (Veit Rubin et al, NAU 2019) also investigated the relationship between vaginal microbiota and the onset of postoperative complications in transvaginal mesh surgery. This retrospective study also found that patients with complications tended to have a greater diversity of microbiota. Furthermore, certain species of bacteria (Veillonella spp) seemed to be commoner in patients with complications. However, this was a low-powered retrospective study with few participants and the results therefore need to be confirmed. Our hypothesis is that the vaginal microbiota may be modified by a surgical act with a vaginal approach. There are very few studies on vaginal microbiota and so far no studies have evaluated the potential impact of a transvaginal surgery on vaginal microbiota. Our study may help to better understand the relationship between the vaginal microbiota and the postoperative evolution of patients.These possible modifications in vaginal microbiota might be predictive of the symptomatology of patients benefitting from transvaginal surgery and play a role in the the post-operative evolution of these patients.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date October 10, 2023
Est. primary completion date January 18, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - All Caucasian menopausal women (not taking hormone substitutes) - Due to undergo transvaginal surgery (as a cure for pelvic organ prolapse or stress urinary incontinence surgery) from the Gynecology departments of Nantes and Nîmes University Hospitals. - Patients must be covered by a health insurance policy - Patients must have given written, informed consent. Exclusion Criteria: - Patients on recent (<1 month) immunosuppressive therapy, - Patients with ongoing antibiotic therapy, - Patients with chronic vaginosis, - Patients on hormone replacement therapy - Patients who have had previous transvaginal mesh surgery. - Patients taking part in another category 1 study for research involving human subjects. - Patients in an exclusion period determined by another study - Patients under court custody, guardianship or curatorship - Patients for whom it has been impossible to give clear information

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Vaginal swabs
On the day of the surgical intervention, vaginal swabs will be taken at various stages of surgery: before vaginal disinfection/draping, directly after disinfection/draping, 1 hour after disinfection, 6 weeks after surgery and 12 months after surgery.
Stool samples
Stool samples will also be taken (and collected in a pot devoted to coproculture with an airtight opaque bag given to the patient) at the inclusion visit on the day before surgery and also 6 weeks after surgery (in a second pot with an airtight opaque bag given to the patient at the time of being discharged).
Urine samples
Urine samples will also be taken before surgery and 6 weeks after surgery.

Locations

Country Name City State
France Centre Hospitalier Universitaire Nîmes Gard

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Classes of vaginal flora before surgery A vaginal swab will be taken before surgery and the sample will be analyzed by DNA sequencing in order to classify the microbiota into community state types. Day 1
Primary Classes of vaginal flora 6 weeks after surgery A vaginal swab will be taken 6 weeks after surgery and the sample will be analyzed by DNA sequencing in order to classify the microbiota into community state types. Day 42
Secondary Classes of vaginal flora 12 mois after surgery A vaginal swab will be taken 12 months after surgery and the sample will be analyzed by DNA sequencing in order to classify the microbiota into community state types. Month 12
Secondary Alphadiversity of vaginal flora before preparation for surgery measured with the Shannon index A vaginal swab will be taken before any preparation for surgery has begun and the alphadiversity of the microbiota will be measured according to the Shannon index in Taxonomic Operational Units Day 1
Secondary Betadiversity of vaginal flora before preparation for surgery measured with the Bray-Curtis index A vaginal swab will be taken before any preparation for surgery has begun and the betadiversity of the microbiota will be measured according to the Bray-Curtis index in Taxonomic Operational Units Day 1
Secondary Alphadiversity of vaginal flora directly after disinfection and draping, measured with the Shannon index A vaginal swab will be taken directly after disinfection and draping and the alphadiversity of the microbiota will be measured according to the Shannon index in Taxonomic Operational Units. Day 1
Secondary Betadiversity of vaginal flora directly after disinfection and draping, measured with the Bray-Curtis index A vaginal swab will be taken directly after disinfection and draping and the betadiversity of the microbiota will be measured according to the Bray-Curtis index in Taxonomic Operational Units. Day 1
Secondary Alphadiversity of vaginal flora one hour after disinfection and draping, measured with the Shannon index A vaginal swab will be taken one hour after disinfection and draping and the alphadiversity of the microbiota will be measured according to the Shannon index in Taxonomic Operational Units. Day 1
Secondary Betadiversity of vaginal flora one hour after disinfection and draping, measured with the Bray-Curtis index A vaginal swab will be taken one hour after disinfection and draping and the betadiversity of the microbiota will be measured according to the Bray-Curtis index in Taxonomic Operational Units. Day 1
Secondary Alphadiversity of vaginal flora six weeks after surgery, measured with the Shannon index A vaginal swab will be taken six weeks after surgery and the alphadiversity of the microbiota will be measured according to the Shannon index in Taxonomic Operational Units. Day 42
Secondary Betadiversity of vaginal flora six weeks after surgery, measured with the Bray-Curtis index A vaginal swab will be taken six weeks after surgery and the betadiversity of the microbiota will be measured according to the Bray-Curtis index in Taxonomic Operational Units. Day 42
Secondary Alphadiversity of vaginal flora twelve months after surgery, measured with the Shannon index A vaginal swab will be taken twelve months after surgery and the alphadiversity of the microbiota will be measured according to the Shannon index in Taxonomic Operational Units. Month 12
Secondary Betadiversity of vaginal flora twelve months after surgery, measured with the Bray-Curtis index A vaginal swab will be taken twelve months after surgery and the betadiversity of the microbiota will be measured according to the Bray-Curtis index in Taxonomic Operational Units. Month 12
Secondary Prolapse. Feeling a bulge six weeks after surgery Yes/No. If present, this will be classified according to the International Continence Society-International Urogynecological Association classification Day 42
Secondary Prolapse. Feeling a bulge twelve months after surgery Yes/No. If present, this will be classified according to the International Continence Society-International Urogynecological Association classification Month 12
Secondary Dyspareunia six weeks after surgery Yes/no. If present, this will be rated according to the International Continence Society-International Urogynecological Association classification. Day 42
Secondary Dyspareunia 12 months after surgery Yes/No. If present, this will be rated according to the International Continence Society-International Urogynecological Association classification. Month 12
Secondary Pain six weeks after surgery The patient will be asked to evaluate pain according to a visual analogue scale ranging from 0 (no pain) to 10 (extremely painful). Day 42
Secondary Pain 12 months after surgery The patient will be asked to evaluate pain according to a visual analogue scale ranging from 0 (no pain) to 10 (extremely painful). Month 12
Secondary Urinary incontinence upon effort six weeks after surgery Yes/No. If present, this will be rated according to the International Continence Society-International Urogynecological Association classification. Day 42
Secondary Urinary incontinence upon effort 12 months after surgery Yes/No.If present, this will be classified according to the International Continence Society-International Urogynecological Association classification Month 12
Secondary Need to urinate urgently six weeks after surgery Yes/No.If present, this will be classified according to the International Continence Society-International Urogynecological Association classification. Day 42
Secondary Need to urinate urgently 12 months after surgery Yes/No.If present, this will be classified according to the International Continence Society-International Urogynecological Association classification. Month 12
Secondary Dysuria 6 weeks after surgery Yes/No.If present, this will be classified according to the International Continence Society-International Urogynecological Association classification. Day 42
Secondary Dysuria 12 months after surgery Yes/No.If present, this will be classified according to the International Continence Society-International Urogynecological Association classification. Month 12
Secondary Constipation 6 weeks after surgery Yes/No. If present, this will be classified according to the International Continence Society-International Urogynecological Association classification. Day 42
Secondary Constipation 12 months after surgery Yes/No. If present, this will be classified according to the International Continence Society-International Urogynecological Association classification. Month 12
Secondary Anal incontinence 6 weeks after surgery Yes/No. If present, this will be classified according to the International Continence Society-International Urogynecological Association classification. Day 42
Secondary Anal incontinence 12 months after surgery Yes/No. If present, this will be classified according to the International Continence Society-International Urogynecological Association classification. Month 12
Secondary Presence or absence of complications 6 weeks after surgery Yes/No. If present, these will be rated according to the Clavien Dindo classification. The Clavien Dindo classification is a scale with grades ranging from 1 to 5 in which Grade 1 = any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside. Grade 5 = death of the patient. Day 42
Secondary Presence or absence of complications 12 months after surgery Yes/No. If present, these will be rated according to the Clavien Dindo classification.The Clavien Dindo classification is a scale with grades ranging from 1 to 5 in which Grade 1 = any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside. Grade 5 = death of the patient. Month 12
Secondary Presence or absence of complications related to a prosthesis 6 weeks after surgery Yes/No. If present, these will be rated according to the International Continence Society-International Urogynecological Association classification Day 42
Secondary Presence or absence of complications related to a prosthesis 12 months after surgery Yes/No. If present, these will be rated according to the International Continence Society-International Urogynecological Association classification. Month 12
Secondary Presence or absence of infection at the operating site 6 weeks after surgery Yes/No Day 42
Secondary Presence or absence of infection at the operating site 12 months after surgery Yes/No Month 12
Secondary Urine sample before surgery A urine sample will be collected from the patient before surgery and stored in a sterile pot at -80° at the Biological resource Centre at Nîmes or Nantes University Hospitals. Day 1
Secondary Urine sample after vaginal disinfection and surgical draping. A urine sample will be collected from the patient before surgery but after vaginal disinfection and surgical draping, and stored in a sterile pot at -80° at the Biological resource Centre at Nîmes or Nantes University Hospitals. Day 1
Secondary Urine sample 6 weeks after surgery six weeks after surgery A urine sample will be collected from the patient 6 weeks after surgery and stored in a sterile pot at -80° at the Biological resource Centre at Nîmes or Nantes University Hospitals. Day 42
Secondary Urine sample 12 months after surgery A urine sample will be collected from the patient 12 months after surgery and stored in a sterile pot at -80° at the Biological resource Centre at Nîmes or Nantes University Hospitals. Month 12
Secondary Stool sample before surgery The day before surgery, at the inclusion visit, a stool sample will be collected in a sterile pot and stored at -80° at the Biological resource Centre at Nîmes or Nantes University Hospitals. Day 0
Secondary Stool sample 6 weeks after surgery Six weeks after surgery, a stool sample will be collected in a sterile pot and stored at -80° at the Biological resource Centre at Nîmes or Nantes University Hospitals. Day 42
See also
  Status Clinical Trial Phase
Recruiting NCT06140238 - Preemptive Analgesic Efficacy of Parecoxib for Reducing Postoperative Pain in Gynecological Surgery Phase 4
Not yet recruiting NCT03644992 - An Analysis Into the Cause and Preventional Method of Thromboembolic Disease in Gynecological Surgery
Recruiting NCT01953627 - Laparoscopic Gynecologic Surgery With Robotic Assistance System Kymerax® : Pilot Study N/A
Completed NCT01546272 - Medico-economic Evaluation of Subcutaneous Automatic Resorbable Staples Device Phase 3
Recruiting NCT06385002 - Effect of Combined Administration of Sevoflurane and Remimazolam on Emergence N/A
Completed NCT00997295 - Heat and Moisture Exchanger and Low-flow Gas N/A
Completed NCT01285622 - Plethysmography Variability Index as an Indicator of Adequacy of Preload
Completed NCT02855567 - Acupuncture for Post-Operative Pain Control for Patients Undergoing Gynecological Surgery N/A